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β-Lactoglobulin (BLG) like other lipocalins can be modi-
fied by mutagenesis to re-direct its ligand binding 
properties. Local site-directed mutagenesis was used to 
change the geometry of the BLG ligand binding pocket 
and therefore change BLG ligand preferences. The pre-
sented studies are focused on previously described 
mutants L39Y, I56F, L58F, F105L, and M107L and two 
new BLG variants, L39K and F105A, and their interac-
tions with local anesthetic drug tetracaine. Binding of 
tetracaine to BLG mutants was investigated by X-ray 
crystallography. Structural analysis revealed that for tet-
racaine binding, the shape of the binding pocket seems 
to be a more important factor than the substitutions in-
fluencing the number of interactions. Analyzed BLG mu-
tants can be classified according to their binding prop-
erties to variants: capable of binding tetracaine in the 
β-barrel (L58F, M107L); capable of accommodating tet-
racaine on the protein surface (I56F) and unable to bind 
tetracaine (F105L). Variants L39K, L39Y, and F105A, had 
a binding pocket blocked by endogenous fatty acids. 
The new tetracaine binding site was found in the I56F 
variant. The site localized on the surface near Arg124 
and Trp19 was previously predicted by in silico studies 
and was confirmed in the crystal structure.
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INTRODUCTION
β-Lactoglobulin (BLG), a small globular protein be-
longing to a lipocalin family, like other lipocalins can be 
modified by mutagenesis to re-direct its ligand binding 
specificity (Deuschle et al., 2020). Human lipocalins are 
usually modified by randomization of flexible loops sur-
rounding β-barrel to create highly specific proteins with 
potential medical applications called Anticalins (Rothe & 
Skerra, 2018). In our studies, local site-directed mutagen-
esis was used to change the geometry of the BLG ligand 
binding pocket and therefore change its ligand prefer-
ences (Loch et al., 2018; Bonarek et al., 2020). Detailed 
physicochemical characteristics of seven new lactoglob-
ulin mutants (L39Y, I56F, L58F, V92F, V92Y, F105L, 
and M107L) as well as crystal structure of five of these 
variants and their complexes with selected fatty acids 
have been published elsewhere (Bonarek et al., 2020). 
Crystallographic investigations revealed significant chang-
es of the binding pocket shape in two mutants, I56F and 
F105L. In both variants, the binding site was shorter 
than in the wild-type (WT) protein. The presence of a 
rigid aromatic ring introduced at position 56 prevent-
ed the binding of fatty acids by I56F variant, while in 
F105L variant the binding ability was retained due to the 
higher flexibility of the binding pocket (Bonarek et al., 
2020). Interestingly, fatty acid bound by F105L variant 
had unusual bent conformation, not observed previously 
in any other lactoglobulin structures, indicating adjust-
ment of both binding pocket and ligand conformation. 
Variants L39Y, L58F and M107L retained the elongated 
shape of the binding pocket, very similar to the one pre-
sent in WT protein. Their ability to bind fatty acids was 
confirmed by crystal structures revealing the presence of 
a single fatty acid molecule bound in an extended con-
formation in the β-barrel (Bonarek et al., 2020).
Fatty acids are considered to be the natural ligands of 
lactoglobulin, so their interactions with modified BLG 
were investigated first. However, in the course of our 
systematic studies (Loch et al., 2011; Loch et al., 2012; 
Loch et al., 2013b; Loch et al., 2013a; Loch et al., 2014; 
Loch et al., 2015b) aimed to investigate the binding of 
different ligands to natural lactoglobulin isolated from 
cow, goat, and sheep milk, we showed that derivatives 
of fatty acids and the model drug, tetracaine (TET), can 
also be accepted by the binding pocket. Tetracaine, a 
model amphiphilic ligand possessing an elongated struc-
ture with two short aliphatic fragments and an aromatic 
ring, is classified as a local anesthetic drug. Tetracaine 
binds to natural bovine BLG with an affinity lower than 
fatty acids (Loch et al., 2015a). Crystal structures revealed 
that TET is bound in the BLG β-barrel in the same way 
as fatty acids, even though it has a bulky aromatic ring 
in its structure and is less flexible than aliphatic com-
pounds.
The studies presented here are a continuation and ex-
tension of our previous work aimed to fully characterize 
new lactoglobulin mutants with a binding pocket modi-
fied by a single mutation (Bonarek et al., 2020). This re-
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port is focused on previously described mutants L39Y, 
I56F, L58F, F105L, and M107L (Bonarek et al., 2020) 
and two new variants, L39K and F105A (Fig. 1). The 
L39K mutant was created to enhance positive charge at 
the entrance to the binding pocket in close proximity to 
two other lysines. It can be considered as an alternative 
to the L39Y which had increased thermal stability, but 
its binding site was permanently blocked by an endoge-
nous fatty acid. The second variant, F105A was designed 
to enlarge the binding pocket which in previously char-
acterized variant F105L was shortened but could accom-
modate aliphatic ligand in a bent conformation.
Ligand binding by lactoglobulin, although quite spe-
cific and selective, is in most cases entropically-driven 
(Loch et al., 2011; Loch et al., 2012; Loch et al., 2013a; 
Loch et al., 2015a). The simplest method to determine li-
gand affinity is the use of ITC, which is time-consuming. 
In our previous studies, we noticed that crystallization of 
BLG-ligand complexes usually corresponds well to the 
ITC results, so these two approaches are almost equally 
useful for assessing the ligand binding properties of lac-
toglobulin (Loch et al., 2012; Loch et al., 2013a; Loch et 
al., 2013b; Loch et al., 2015a). Since the crystallization of 
BLG-ligand complexes is relatively fast, inexpensive, and 
reproducible, crystallographic studies were used here as 
the primary approach to probing the TET binding ability 
of new BLG mutants.
METHODS
Protein expression and purification
All lactoglobulin mutants presented in this report were 
produced in E.coli Origami B (DE3) strain using co-
expression with DsbC according to the previously pub-
lished protocol (Loch et al., 2016). Proteins were purified 
using 50 mM phosphate buffer pH 6.5 and a two-step 
chromatographic procedure described elsewhere (Loch et 
al., 2016). Protein purity and homogeneity were checked 
by SDS-PAGE. Prior to crystallization, BLG mutants 
were concentrated using Amicon 10 kDa spin columns. 
Protein concentration was determined spectrophotomet-
rically at 280 nm using molecular weight and absorption 
coefficient calculated individually for each variant with 
the use of ProtParam server (Gasteiger et al., 2005).
Protein crystallization
Proteins were co-crystallized with tetracaine using the 
vapor diffusion method in hanging drop setup. In order 
to identify conditions producing the best quality crystals, 
each mutant was crystallized using solutions containing 
(NH4)2SO4 in the range from 2.0 to 3.0 M (in 0.5 M Tris-
HCl pH from 7.1, 8.0, or 8.5). Drops were set manually 
by mixing 2 μl of protein (usually about 20-24 mg/ml), 
2 μl of the well solution, and 0.5 μl of 10 mM tetracaine 
hydrochloride dissolved in water (Table S1 at https://
ojs.ptbioch.edu.pl/index.php/abp/). Such composition 
of drop corresponds approximately to BLG:TET molar 
ratio of 1:2. The use of higher tetracaine concentration 
was not possible due to its strong precipitation in the 
crystallization drop. Crystals usually grew in 24–48 h, in 
some cases further optimization was required, especially 
if ammonium sulfate solutions did not produce high-
quality crystals. In this case, 1.34 M sodium citrate was 
used as an alternative precipitant. The same procedure 
was used to crystalize unliganded L39K and F105A. De-
tailed crystallization conditions are listed in Table S1 at 
https://ojs.ptbioch.edu.pl/index.php/abp/.
X-ray data collection and structure determination
X-ray diffraction data were collected at SuperNova 
and XtaLAB Synergy-S diffractometers (Rigaku Oxford 
Diffraction) at 100K using CuKα radiation. Crystals were 
cryoprotected using a mixture of glycerol and ethylene 
glycol added to the appropriate crystallization solution. 
X-ray diffraction data were processed using CrysAlis 
software (Rigaku Oxford Diffraction) and Aimless from the 
CCP4 package (Winn et al., 2011). Structures were solved 
by molecular replacement in Phaser (McCoy et al., 2007) 
and refined in Refmac5 (Murshudov et al., 2011). Electron 
density maps were investigated in Coot (Emsley et al., 
2010). Statistics of data collection and structure refine-
ment are summarized in Table S2 at https://ojs.ptbioch.
edu.pl/index.php/abp/. Structures were deposited in 
the Protein Data Bank as entries: 7BGZ, 7BH0, 7BF8, 
7BF7, 7BGX, 7BGA, and 7BF9 (Table S2 at https://ojs.
ptbioch.edu.pl/index.php/abp/).
Circular dichroism
Circular dichroism (CD) spectroscopy was used to 
determine the secondary and tertiary structure of L39K 
and F105A. CD spectra were recorded on a Jasco J-710 
instrument using cells of 5 mm and 200 µm path length 
for near-UV and far-UV measurements, respectively. 
Protein concentrations in the range of 20–86 µM were 
used for measurements. Each spectrum was obtained 
from an average of three scans. Spectra were corrected 
for 50 mM phosphate buffer pH 6.5 contribution and 
normalized to the peptide bond concentration for far-
UV and the protein concentration for near-UV. The sec-
ondary structure composition was estimated using CDPro 
spectra deconvolution software using the CONTINLL 
algorithm and the SDP42 reference spectra data set 
(Sreerama & Woody, 2000). Recorded CD spectra are 
presented in Fig. S1 at https://ojs.ptbioch.edu.pl/index.
php/abp/.
Figure 1. WT BLG molecule (PDB ID: 6QI6) with marked flexible 
loops (AB, CD, EF, GH), β-strands A-H and mutation sites: 39 
(L39K, L39Y), 56 (I56F), 58 (L58F), 105 (F105A, F105L) and 107 
(M107L).
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RESULTS AND DISCUSSION
Structure of L39K and F105A mutants
Circular dichroism (CD) spectroscopy was used to de-
termine the secondary and tertiary structure of F105A 
and L39K variants. The CD spectra of both variants 
were consistent with the results previously obtained 
for the WT protein and other BLG variants (Bonarek 
et al., 2020). The α-helical structure contents were 16% 
and 3% and the β-sheet contents were 34% and 37% 
for F105A and L39K, respectively. The hypsochromic 
broadening of the minimum at about 210 nm in the far-
UV region for L39K results from a lower content of the 
secondary structure. In the near-UV spectrum region 
(240–350 nm) the typical positions of all the extremes 
observed for WT lactoglobulin are preserved, in particu-
lar the minima at 293 and 286 nm, which only changed 
the intensity. The exchange of phenylalanine to alanine 
at position 105 did not affect the CD measurements.
Both new variants, L39K and F105A, crystallized in 
the trigonal space group P3221 with a single protein 
chain in the asymmetric unit. This is the symmetry com-
monly observed for crystals of either natural or recom-
binant β-lactoglobulin (Loch et al., 2012; Bonarek et al., 
2020) The conformation of the main chain is very simi-
lar to WT protein (PDB ID: 6QI6), with r.m.s deviation 
for Cα superposition equal to 0.21 Å (F105A) and 0.22 
Å (L39K). In both structures, the GH loop is partially 
disordered. In F105A, EF loop has open conformation 
that is similar to the one observed in the WT protein 
(r.m.s.d. 0.71 Å).
In the F105A mutant, Ala105 is located at rigid 
β-strand F, not susceptible to movement and its relative-
ly short side chain significantly enlarges the central part 
of the binding pocket (Fig. S2 at https://ojs.ptbioch.edu.
pl/index.php/abp/) without affecting the position of 
surrounding residues. Although the F105A variant was 
crystallized without any ligand addition, a strong elon-
gated electron density was visible in the modified bind-
ing pocket, indicating the presence of a small molecule 
interpreted as endogenous fatty acid originating from the 
expression host. Therefore, F105A is another example 
of a BLG variant with the binding pocket permanently 
blocked by an endogenous fatty acid molecule (Bonarek 
et al., 2020).
The ligand hydrocarbon chain is bent in the region of 
F105A substitution and its end is located near the bot-
tom of the binding pocket. The conformation of the 
fatty acid differs from that observed in structures of un-
modified protein or bent conformation of myristic acid 
in the F105L structure (Fig. S2 at https://ojs.ptbioch.
edu.pl/index.php/abp/). Such a conformation allows 
additional hydrophobic contacts in the enlarged binding 
pocket, which appear to be necessary for stabilization of 
the protein molecule. In the F105L variant, the bent li-
gand conformation resulted from the shorter length of 
the binding pocket and its enlargement in the direction 
of the AB loop (Fig. S2 at https://ojs.ptbioch.edu.pl/in-
dex.php/abp/).
A similar tendency to retain endogenous fatty acid 
in the modified binding pocket was observed for L39Y 
(Bonarek et al., 2020) and L39K variants. Crystallization 
of the L39K in the presence or absence of ligand always 
resulted in a structure showing elongated electron den-
sity in the binding pocket (Fig. S3 at https://ojs.ptbioch.
edu.pl/index.php/abp/). Although this density was a lit-
tle shorter than that observed in F105A or L39Y struc-
tures, it also indicated the presence of endogenous fatty 
acid bound in the β-barrel. The binding site of the L39K 
variant retained its elongated shape very similar to that 
observed in the WT protein (Fig. S3 at https://ojs.pt-
bioch.edu.pl/index.php/abp/). The Lys39 side chain is 
located in the space between AB and GH loops with-
out affecting the conformation of neighboring residues 
and is directed towards the Ser116 carbonyl oxygen. It 
interacts neither with the ligand nor with other protein 
residues.
In our previous study, it was noticed that the L39Y 
variant had increased thermal stability and expression 
yield. It was probably the results of the increased num-
ber of hydrophobic contacts made by Tyr39 and the 
presence of endogenous fatty acid in the β-barrel (Bon-
arek et al., 2020). On the contrary, L39K was expressed 
with a very low efficiency and its CD spectra show de-
creased content of secondary structure indicating partial 
unfolding of protein (Fig. S1 at https://ojs.ptbioch.edu.
pl/index.php/abp/). Also, crystals of L39K mutant dif-
fracted X-rays to 2.40 Å only, while for other variants 
maximum resolution was in the range 2.1–1.8 Å. This 
indicates that the introduction of positively charged Lys 
at position 39 destabilized the BLG structure possibly by 
preventing its interactions with adjacent residues.
Tetracaine binding in the crystalline phase
X-ray crystallography is a method that not only identi-
fies ligands bound to protein but also shows how ligand 
binds and provides information on the protein function, 
dynamics, oligomeric state, and interactions between 
macromolecules (Keedy et al., 2018). Such a complete set 
of data coming from a single experiment is difficult to 
obtain by other methods. The ligand binding by BLG 
is in most cases based on nonspecific hydrophobic in-
teractions and is entropy driven. Therefore, the most 
appropriate method of monitoring the affinity of lacto-
globulin to ligand is ITC, usually combined with the de-
termination of the crystal structure of the protein-ligand 
complex. Our previous studies showed that the crystal-
lization of BLG-ligand complexes usually corresponds 
well to the ITC detection of complex formation. There-
fore, only X-ray crystallography was used in this work to 
monitor the binding of tetracaine to BLG. Crystallization 
of BLG and its mutants is usually very fast, reproducible 
and the obtained crystals diffract X-rays to a resolution 
of 2.0 Å or greater. Considering all these advantages, the 
lactoglobulin variants L39Y, L39K, I56F, L58F, F105L, 
F105A, and M107L (Fig. 1) were co-crystallized with tet-
racaine in a series of experiments. Good quality crystals 
were obtained for most of the mutants and their struc-
ture was solved and refined with maximum resolution in 
the range of 2.1–1.8 Å (except for L39K, Table S2 at 
https://ojs.ptbioch.edu.pl/index.php/abp/). Careful in-
vestigation of the Fourier maps enabled to identify the 
electron density in the β-barrel (Fig. S4 at https://ojs.
ptbioch.edu.pl/index.php/abp/) with the shape and di-
mensions corresponding perfectly to tetracaine in only 
two mutants: L58F and M107L. In these variants, tet-
racaine was bound in the way similar to that observed in 
natural lactoglobulin (Loch et al., 2015a) (Fig. 2). This is 
not surprising, because the binding pocket in both mu-
tants has an elongated shape similar to the one present 
in WT protein. In the M107L variant, a short 4-carbon 
long aliphatic chain of TET is located in the bottom part 
of the binding pocket, the aromatic ring is placed in the 
middle/upper part near residues Val41 and Ile84, while 
a polar fragment possessing tertiary amine was found at 
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the vicinity of the EF loop, close to Asn90. Ligand was 
held in position by hydrophobic contacts with protein 
residues, while its polar part made hydrogen bonds to 
water molecules (Fig. 2).
In the crystal structure of the L58F variant, the li-
gand binding site was the same as in the natural BLG, 
however, due to the presence of a large phenylalanine 
side chain, the tetracaine position was shifted by about 
1 Å towards the β-barrel entrance (Fig. 2C). An electron 
density corresponding to the tetracaine molecule was 
also identified in the I56F variant (Fig. S4 at https://
ojs.ptbioch.edu.pl/index.php/abp/), however, not in the 
β-barrel but on the protein surface (Fig 2). Crystals of 
this variant had unusual orthorhombic symmetry P212121 
(Table S2  at https://ojs.ptbioch.edu.pl/index.php/abp/) 
with protein dimer in the asymmetric unit. The binding 
pocket in the I56F variant (Bonarek et al., 2020) and its 
derivatives I56F/L39A and I56F/L39A/M107F (Loch et 
al., 2018) has a permanently reduced length. The large 
side chain of phenylalanine in position 56 prevents ali-
phatic ligands and tetracaine from binding in the modi-
fied binding pocket. Tetracaine was found on the protein 
surface in the small cavity formed between two protein 
molecules, next to the Arg124 from chain A and Arg124’ 
from chain B’ of the symmetry-related molecule (Fig. 2). 
This observation is in good agreement with in silico pre-
dictions, indicating that binding sites other than β-barrel, 
may include (1) a hydrophobic pocket close to dimer in-
terface in a groove between the α-helix and the β-barrel 
(Yang et al., 2007; Domínguez-Ramírez et al., 2013) or 
(2) the outer surface near Trp19 and Arg124 (Sahihi et 
al., 2013; Liu et al., 2017; Xu et al., 2019). It is highly 
probable that different polar aromatic compounds, e.g. 
p-nitrophenyl phosphate, 5-fluorocytosine or ellipticine, 
can bind to this second site (Sahihi et al., 2013).
Although presented here crystal structure of I56F vari-
ant in complex with tetracaine is the first crystallographic 
evidence of a new binding site on the BLG surface near 
Arg124 and Trp19, this site requires two BLG molecules 
and is available only in the crystalline phase. Neverthe-
less, based on spectroscopic studies, it was proposed 
that some aromatic compounds were bound at a simi-
lar location (Liang & Subirade, 2012; Xu et al., 2019). In 
the presence of TET, the molecular packing in crystals 
of the I56F variant was different than that observed for 
other BLG mutants. Mutation I56F promoted a small 
shifts of atoms in the entire molecule of I56F dimer in 
relation to WT dimer (PDB ID: 6QI6, r.m.s.d. 0.68 Å). 
These shifts are especially visible in the region of the 
β-strands B, C and D, which are located in close neigh-
Figure 2. Interactions of tetracaine with the new lactoglobulin variants. 
TET bound in β-barrel of (A) M107L and (B) L58F mutant. (C) Superposition of M107L (light green), L58F (green) and natural lactoglobulin 
(PDB ID: 4Y0P, light pink). (D) TET bound on the surface of I56F variant. (E) The binding pocket shape in I56F mutant and TET binding 
site on I56F surface. (F) A single TET molecule trapped between two I56F dimers in the crystalline phase. All 2FoFc maps are shown at 
1.00 σ level (omit maps calculated for ligands are presented in Fig. S4 at https://ojs.ptbioch.edu.pl/index.php/abp).
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borhood of the TET binding site (Fig. S5 at https://ojs.
ptbioch.edu.pl/index.php/abp/).
The I56F mutation seems to be the crucial factor for 
these changes as the crystal structure of another variant 
with reduced binding pocket size, the F105L, not pos-
sessing TET in both the β-barrel and on the protein 
surface, showed typical trigonal symmetry (Bonarek et al., 
2020). X-ray diffraction data collected for F105L crystals 
obtained in two independent co-crystallization experi-
ments always showed similar results: only small peaks of 
the electron density, interpreted as cryoprotectant mol-
ecules (glycerol), were found on the Fourier maps in the 
β-barrel (Fig. S3 at https://ojs.ptbioch.edu.pl/index.php/
abp/). These observations indicate that the relatively 
flexible binding pocket in F105L is too small to accom-
modate the rigid TET molecule, although it was able to 
accommodate the fatty acid in the bent conformation 
(Bonarek et al., 2020).
The co-crystallization of TET with L39Y, L39K, and 
F105A variants, resulted in the growth of good-quality 
trigonal crystals. The electron density maps revealed in 
all these structures the presence of elongated electron 
density in the β-barrel (Fig. S3 at https://ojs.ptbioch.
edu.pl/index.php/abp/). Such a density is typical for en-
dogenous fatty acid blocking the binding pocket. These 
observations indicate that TET is not able to compete 
with endogenous fatty acids and displace them from the 
β-barrel. As these structures are almost identical to those 
obtained in the absence of ligand, we decided to include 
in this work the structures of L39K and F105A crystal-
lized without ligand and structures of L39Y and F105L 
obtained in the presence of TET, as these structures 
have better resolution and overall quality than those pre-
viously deposited in the PDB (ID: 6QI7 and 6XVE).
CONCLUSIONS
X-ray crystallography was used to test the binding of 
the model ligand, tetracaine, to several BLG variants. 
High quality electron density maps allowed to unambigu-
ously identify the type of a ligand bound in the β-barrel 
or at the protein surface. According to the results of the 
crystal structure analysis, mutants can be divided into 
four groups: [1] capable of binding TET in the β-barrel 
in a manner similar to natural protein (L58F, M107L); 
[2] capable of accommodating tetracaine on the protein 
surface (I56F); [3] unable to bind TET (F105L) and [4] 
variants with a binding pocket blocked by endogenous 
fatty acids (L39K, L39Y, F105A). The obtained results 
have been compared with the previously published (Bon-
arek et al., 2020) binding properties of BLG variants and 
are summarized in Table S3 (at https://ojs.ptbioch.edu.
pl/index.php/abp/).
Of the seven variants analyzed (Table S3 at https://
ojs.ptbioch.edu.pl/index.php/abp/), in three cases, 
L39K, L39Y, and F105A, the binding pocket was 
blocked by endogenous fatty acid. In two other variants, 
L58F and M107F, both the fatty acid and tetracaine 
were bound in the binding pocket retaining its elongated 
shape. The significant differences were observed for two 
variants, I56F and F105L, with reduced length of the 
binding pocket. The I56F variant did not bind fatty acid 
or tetracaine in the β-barrel, but the tetracaine was found 
on the surface in the cavity formed between two protein 
molecules. This unusual ligand binding was accompanied 
by a different crystal symmetry than that observed for 
other variants. In the crystal structure of the F105L vari-
ant, the fatty acid was bound in the β-barrel in a bent 
conformation (Bonarek et al., 2020). Such a conforma-
tion is not accessible for the tetracaine molecule and that 
made it impossible to bind in the β-barrel.
It can be concluded that for tetracaine binding, the 
shape of the binding pocket seems to be a more impor-
tant factor than the substitutions influencing the number 
of protein-ligand interactions in the β-barrel.
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